Increasing pressures for drug developers to produce novel new therapies at an accelerated pace— under tightened R&D budgets is a conversation occurring on a global scale. Innovation in compounds for the industry is giving rise to new breed of partnerships. These relationships are revamping legacy cost models. New outsourcing models must be designed to address study complexity while maintaining an efficient budget with accelerated timelines. When managing an outsourcing partner, evaluating the scope and extent to which these partnerships can contribute to a positive bottom line requires understanding the critical processes of managing study steps with an eye to improved costs. The extent to which sponsors and CROs can work effectively together to select the proper outsourcing model will ultimately lower the non-clinical costs of managing the R&D process.